Robert E. Hoffman - 20 Mar 2026 Form 4 Insider Report for CytoDyn Inc. (CYDY)

Reporting relationship: Chief Financial Officer
Issuer ticker: CYDY
Reported as of: 20 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Mar 2026, 17:22:09 UTC
Prior SEC filing: 17 Feb 2026
Next SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Blok, attorney-in-fact for Robert E. Hoffman

Key filing fact

Robert E. Hoffman filed Form 4 for CytoDyn Inc. (CYDY) on 24 Mar 2026.

Key facts

This page summarizes Robert E. Hoffman's Form 4 filing for CytoDyn Inc. (CYDY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Mar 2026, 17:22.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001166288 Primary reporting owner

Hoffman Robert E.

Relationship: Chief Financial Officer
Address: 1111 MAIN STREET, SUITE 660, VANCOUVER
Signature: /s/ Tyler Blok, attorney-in-fact for Robert E. Hoffman
Signature date: 24 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYDY transaction Derivative

Non-qualified stock option (right to buy)

Award

Transaction value
Shares: +4,874,691
Change %
Price: $0.000000^*
Shares after: 4,874,691
Date: 20 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,874,691
Exercise price: $0.2800
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").

Footnote F2

1,218,672 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030.